|
|
 |
 |
|
|
Avastin™ (bevacizumab) Pre-filled syringes for Macular Degeneration Treatment Avastin™ (bevacizumab) is an FDA approved injectable drug for the treatment of colon cancer. Avastin™ (bevacizumab) is one of a class of drugs called Anti-VEGF (Vascular Endothelial Growth Factor). This drug reduces the growth of abnormal blood vessels. Avastin™ (bevacizumab) is being used by retinal specialists (as an off-label use) in the treatment of wet macular degeneration, or AMD. AMD exists in two forms, dry Age-related Macular Degeneration and wet Age-related Macular Degeneration. Wet AMD is a serious, vision-threatening condition. In wet AMD abnormal blood vessels behind the retina start to grow in the area of the retina known as the macula. These blood vessels leak blood and fluid causing damage to the macula and loss of vision. Two published studies (see below) have shown Avastin™ (bevacizumab) to benefit macular degeneration patients whose eye were treated with Avastin™ (bevacizumab) injections. In both studies the drug was reported to be well tolerated. Published results of initial trials of Avastin™ (bevacizumab) for the treatment of wet Age-related Macular Degeneration have reported promising results. A study conducted by Dr. Philip J Rosenfeld, MD, PhD, associate professor of ophthalmology at Bascom Palmer Eye Institute, showed the eye treated with Avastin™ (bevacizumab) improved significantly. While there are a few other treatments for wet Age-related Macular Degeneration, eyes treated with Avastin™ (bevacizumab) were reported to improve vision in as little as one week according to Dr. Rosenfeld. Retinal specialists use a very small amount of Avastin™ (bevacizumab). Typically, the retinal specialist will ask a compounding pharmacy specializing in sterile (aseptic) compounding (such as Wedgewood Pharmacy) to transfer the Avastin™ (bevacizumab) from the manufacturer's vial into prefilled syringes containing a single dose. This injection is then administered by the retinal specialist , usually in an office setting. Published Studies: Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005 Jun;112(6):1035-47. References:
The information contained on this site is general in nature
and is intended for use as an informational aid. It does not cover all possible
uses, actions, precautions, side effects, or interactions of the products shown,
nor is the information intended as medical advice or diagnosis for individual
health problems or for making an evaluation as to the risks and benefits of
using a particular product. You should consult your doctor about diagnosis and
treatment of any health problems. Information and statements have not been evaluated
by the Food and Drug Administration ("FDA"), nor has the FDA approved
the products to diagnose, cure or prevent disease. Caring for People | Veterinary
Medicine | Due Diligence | HIPAA Privacy Notice | Home
Wedgewood
Pharmacy |
|||||||||
